Mitogen-activated protein kinase kinase kinase
From Proteopedia
(Difference between revisions)
| (6 intermediate revisions not shown.) | |||
| Line 2: | Line 2: | ||
== Function == | == Function == | ||
| - | [[Mitogen-activated protein kinase kinase kinase]] (MAP3K) are serine/threonine kinases which regulate various cellular activities in response to extracellular stimuli by mitogens, heat shock and more. MAP3K is part of the MAPK cascade which consists also of [[Mitogen-activated protein kinase|MAPK]] and [[Mitogen-activated protein kinase kinase|MAP2K]] which are activated by phosphorylation. MAP3K activates [[Mitogen-activated protein kinase kinase|MAP2K]]<ref>PMID:9006902</ref>. | + | [[Mitogen-activated protein kinase kinase kinase]] or '''DLK''' (MAP3K) are serine/threonine kinases which regulate various cellular activities in response to extracellular stimuli by mitogens, heat shock and more. MAP3K is part of the MAPK cascade which consists also of [[Mitogen-activated protein kinase|MAPK]] and [[Mitogen-activated protein kinase kinase|MAP2K]] which are activated by phosphorylation. MAP3K activates [[Mitogen-activated protein kinase kinase|MAP2K]]<ref>PMID:9006902</ref>. |
| + | *'''MAP3K1''' regulates cell migration and contributes to pro-survival signaling<ref>PMID:24386504</ref>. | ||
| + | *'''MAP3K10''' has a role in the tumorugenesis of pancreatic ductal adenocarcinoma<ref>PMID:23178452</ref>. | ||
| + | *'''MAP3K14''' is a regulator of enforced viral replication in the spleen<ref>PMID:32033109</ref>. | ||
== Disease == | == Disease == | ||
| Line 12: | Line 15: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | * MAP3K1 | + | * MAP3K1; Domains – kinase 10-307; SH3-binding 465-480; TOG 648-867 |
| - | **[[1uti]] - MAP3K1+GRB2-related adaptor protein 2 - mouse | + | **[[6nfy]], [[6nfz]] - hMAP3K1 kinase domain + cancer drug - human<br /> |
| + | **[[6ng0]] - hMAP3K1 kinase domain (mutant) + cancer drug <br /> | ||
| + | **[[6nyb]] - hMAP3K1 kinase domain (mutant) + B-raf + 14-3-3 protein ζ – Cryo EM<br /> | ||
| + | **[[6whb]] - hMAP3K1 TOG domain + cancer drug <br /> | ||
| + | |||
| + | **[[1uti]] - MAP3K1 SH3-binding domain +GRB2-related adaptor protein 2 - mouse | ||
*MAP3K2 | *MAP3K2 | ||
| - | **[[2cu1]] - hMAP3K2 PB1 domain (mutant) | + | **[[2cu1]] - hMAP3K2 PB1 domain (mutant) - NMR<br /> |
| - | **[[2o2v]], [[5uoj]] – hMAP3K2+ | + | **[[2o2v]], [[5uoj]] – hMAP3K2+hMAP3K<br /> |
**[[2npt]] - hMAP3K2 PHOX domain + hMAP2K5 PHOX domain | **[[2npt]] - hMAP3K2 PHOX domain + hMAP2K5 PHOX domain | ||
| Line 28: | Line 36: | ||
**[[2pph]] - hMAP3K3 PB1 domain - NMR | **[[2pph]] - hMAP3K3 PB1 domain - NMR | ||
| - | *MAP3K5 | + | *MAP3K5 (Ask1; Apoptosis signal-regulating kinase 1) |
**[[2clq]] – hMAP3K5<br /> | **[[2clq]] – hMAP3K5<br /> | ||
| - | **[[4bf2]], [[4bhn]], [[4bib]], [[4bic]], [[4bid]], [[4bie]] - hMAP3K5 (mutant) + inhibitor<br /> | + | **[[6oyt]], [[6vre]], [[6xih]], [[7mu7]] - hMAP3K5 + inhibitor<br /> |
| + | **[[4bf2]], [[4bhn]], [[4bib]], [[4bic]], [[4bid]], [[4bie]], [[6e2m]], [[6e2n]], [[6e2o]], [[6oyw]] - hMAP3K5 (mutant) + inhibitor<br /> | ||
*MAP3K7 (TAK1) | *MAP3K7 (TAK1) | ||
**[[2eva]] – hMAP3K7/MAP3K7-interacting protein 1<br /> | **[[2eva]] – hMAP3K7/MAP3K7-interacting protein 1<br /> | ||
| - | **[[ | + | **[[2y1y]], [[4gs4]], [[4l3p]], [[4l52]], [[4l53]], [[4o91]], [[5gjd]], [[5gjf]], [[5gjg]], [[5e7r]], [[5jga]], [[5jgb]], [[5jgd]], [[7nth]] - hMAP3K7/MAP3K7-interacting protein 1 + inhibitor<br /> |
*MAP3K9 | *MAP3K9 | ||
| Line 46: | Line 55: | ||
**[[2rf0]] - hMAP3K10 SH3 domain - NMR | **[[2rf0]] - hMAP3K10 SH3 domain - NMR | ||
| - | *MAP3K14 | + | *MAP3K11 |
| + | |||
| + | **[[6cq7]] - hMAP3K11 SH3 domain/huntington fusion peptide<br /> | ||
| + | |||
| + | *MAP3K12 kinase domain 115-402 | ||
| + | |||
| + | **[[5cen]] - hMAP3K12 <br /> | ||
| + | **[[5ceo]], [[8deg]] - hMAP3K12 + inhibitor<br /> | ||
| + | |||
| + | *MAP3K14 kinase domain 343-686 (NIK) | ||
**[[4dn5]] - hMAP3K14 (mutant) + ATP-γ-S<br /> | **[[4dn5]] - hMAP3K14 (mutant) + ATP-γ-S<br /> | ||
| - | **[[4idt]], [[4idv]] - hMAP3K14 + inhibitor<br /> | + | **[[4idt]], [[4idv]], [[6wpp]], [[6z1q]], [[6z1t]] - hMAP3K14 + inhibitor<br /> |
| + | **[[6g4y]], [[6g4z]], [[6myn]], [[7szr]] - mMAP3K14 + inhibitor<br /> | ||
| + | |||
| + | *MAP3K15 | ||
| + | |||
| + | **[[6v0m]] - hMAP3K15 residues 1241-1308<br /> | ||
| + | |||
| + | *MAP3K MLT | ||
| + | |||
| + | **[[6jut]], [[6juu]] - hMAP3K + inhibitor<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
3D Structures of Mitogen-activated protein kinase kinase kinase
Updated on 11-July-2024
References
- ↑ Ellinger-Ziegelbauer H, Brown K, Kelly K, Siebenlist U. Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem. 1997 Jan 31;272(5):2668-74. PMID:9006902
- ↑ Pham TT, Angus SP, Johnson GL. MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes Cancer. 2013 Nov;4(11-12):419-26. PMID:24386504 doi:10.1177/1947601913513950
- ↑ An Y, Cai B, Chen J, Lv N, Yao J, Xue X, Tu M, Tang D, Wei J, Jiang K, Wu J, Li Q, Gao W, Miao Y. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett. 2013 Feb 28;329(2):228-35. PMID:23178452 doi:10.1016/j.canlet.2012.11.005
- ↑ Hamdan TA, Bhat H, Cham LB, Adomati T, Lang J, Li F, Murtaza A, Hardt C, Lang PA, Duhan V, Lang KS. Map3k14 as a Regulator of Innate and Adaptive Immune Response during Acute Viral Infection. Pathogens. 2020 Feb 4;9(2):96. PMID:32033109 doi:10.3390/pathogens9020096
- ↑ Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56. PMID:11897507
